Inhibition of HER1 signaling pathway enhances antitumor effect of endocrine therapy in breast cancer

被引：24

作者：

Kurebayashi J. ^{[1
]}

Okubo S. ^{[1
]}

Yamamoto Y. ^{[1
]}

Sonoo H. ^{[1
]}

机构：

[1] Department of Breast and Thyroid Surgery, Kawasaki Medical School, Kurashiki, Okayama 701-0192

来源：

Breast Cancer | 2004年 / 11卷 / 1期

关键词：

Antiestrogen; Breast cancer; Endocrine therapy; HER1; Tyrosine kinase inhibitor;

D O I：

10.1007/BF02968000

中图分类号：

学科分类号：

摘要：

Epidermal growth factor receptor (EGFR)/HER1 is expressed at high levels in at least 20% of breast cancers. This high expression correlates with a poor prognosis in patients with breast cancer. Experimental and clinical findings suggest that aberrant activation of tyrosine receptor kinases, such as HER1 pathway, play a causal role in the development of antiestrogen resistance in breast cancer. Recent preclinical and clinical evidence shows that inhibition of growth factor signaling pathways suppresses the growth of malignant cells without serious toxicities. To test the hypothesis that inhibition of the HER1 signaling pathway enhances the antitumor effect of endocrine therapy, a promising signal transduction inhibitor (STI) of HER1 tyrosine kinase, gefitinib, and an estrogen receptor (ER) antagonist, fulvestrant, were administered to human breast cancer cells. Our experimental results have revealed that gefitinib additively enhances the antitumor effect of fulvestrant in estrogen receptor (ER)-positive breast cancer cells under estrogen-supplemented conditions. An additive increase in the protein expression level of a cyclindependent kinase inhibitor, p21 may play a key role of this additive cytostatic effect. The rationale and future perspectives of the combined use of STIs with endocrine therapy in breast cancer are discussed.

引用

页码：38 / 41

页数：3

共 23 条

[1]

Kurebayashi J., Biological and clinical significance of HER2 overexpression in breast cancer, Breast Cancer, 8, pp. 45-51, (2001)

[2]

Yarden Y., Sliwkowski M.X., Untangling the ErbB signaling network, Nat Rev Mol Cell Biol, 2, pp. 127-137, (2001)

[3]

Arteaga C.L., Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia, Seminars in Oncology, 29, SUPPL. 14, pp. 3-9, (2002)

[4]

Kurebayashi J., Endocrine-resistant breast cancer: Underlying mechanisms and strategies for overcoming resistance, Breast Cancer, 10, pp. 112-119, (2003)

[5]

Nicholson S., Halcrow P., Farndon J.R., Sainsbury J.R.C., Chambers P., Harris A.L., Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer, Lancet, 1, 8631, pp. 182-185, (1989)

[6]

Van Agthoven T., Van Agthoven T.L., Portengen H., Foekens J.A., Dorssers L.C., Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-1 human breast cancer cells, Cancer Res, 52, pp. 5082-5088, (1992)

[7]

Kato S., Endoh H., Masuhiro Y., Kitamoto T., Uchiyama S., Sasaki H., Masushige S., Gotoh Y., Nishida E., Kawashima H., Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase, Science, 270, pp. 1491-1494, (1995)

[8]

Bunone G., Briand P.-A., Miksicek R.J., Picard D., Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation, EMBO Journal, 15, 9, pp. 2174-2183, (1996)

[9]

Chen D., Riedl T., Washbrook E., Pace P.E., Coombes R.C., Egly J.M., Ali S., Activation of estrogen receptor alpha by S118 phosphorylation involves a liganddependent interaction with TFIIH and participation of CDK7, Mol Cell, 6, pp. 127-137, (2000)

[10]

Kurokawa H., Arteaga C.L., Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer, Clinical Cancer Research, 7, SUPPL. 12, (2001)

← 1 2 3 →